Novo Nordisk Navigates a Pivotal Summer: Medicare Access, Pipeline Milestones, and Cyberattack Fallout

For Novo Nordisk, the next few weeks represent a rare convergence of regulatory, commercial, and clinical catalysts that could reshape its growth trajectory. The most transformative near-term event is the imminent opening of Medicare’s coffers to obesity drugs — a policy shift that, after more than two decades of exclusion, stands to broaden the Danish [...] The post Novo Nordisk Navigates a Pivotal Summer: Medicare Access, Pipeline Milestones, and Cyberattack Fallout appeared first on NewsCase